PFE - Johnson & Johnson to acquire ADC developer Ambrx Biopharma for $2B
2024-01-08 07:52:26 ET
More on Johnson & Johnson
- Johnson & Johnson: Overblown Stelara Concerns Distract From Value
- Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook
- Johnson & Johnson: A Defensive Dividend King Set To Outperform The S&P 500
- Dividend Roundup: Johnson & Johnson, AT&T, Mastercard, PNC Financial, and more
- 4 stocks to watch on Wednesday: Apple, Moderna and more
For further details see:
Johnson & Johnson to acquire ADC developer Ambrx Biopharma for $2B